Interferons and their potential in the treatment of ocular inflammation

References

• IsaacsALindenmannJVirus interference. I. The interferonProc R Soc Lond B Biol Sci195714792725826713465720
   PubMed Web of Science ®Google Scholar
• BaccalaRKonoDHTheofilopoulosANInterferons as pathogenic effectors in autoimmunityImmunol Rev200520492615790347
   PubMed Web of Science ®Google Scholar
• AdlaMHepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literatureDig Dis Sci200853102810281218320314
   PubMed Web of Science ®Google Scholar
• DoychevaDInterferon-alpha-associated presumed ocular sarcoidosisGraefes Arch Clin Exp Ophthalmol2009247567568019034483
   PubMed Web of Science ®Google Scholar
• LublinFHistory of modern multiple sclerosis therapyJ Neurol2005252Suppl 3iii3iii916170498
   PubMedGoogle Scholar
• TheofilopoulosANType I interferons (alpha/beta) in immunity and autoimmunityAnnu Rev Immunol20052330733615771573
   PubMed Web of Science ®Google Scholar
• BaccalaRTLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunityNat Med200713554355117479100
   PubMed Web of Science ®Google Scholar
• BanchereauJPascualVType I interferon in systemic lupus erythematosus and other autoimmune diseasesImmunity200625338339216979570
   PubMed Web of Science ®Google Scholar
• DevendraDEisenbarthGSInterferon alpha – a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunityClin Immunol2004111322523315183143
   PubMed Web of Science ®Google Scholar
• BennettLInterferon and granulopoiesis signatures in systemic lupus erythematosus bloodJ Exp Med2003197671172312642603
   PubMed Web of Science ®Google Scholar
• SteinmanLA brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damageNat Med200713213914517290272
   PubMed Web of Science ®Google Scholar
• AdamusGMyelin basic protein specific T-Helper cells induce experimental anterior uveitisJ Neurosci Res19964465135188794942
   PubMed Web of Science ®Google Scholar
• VerhagenCT cell immunity to myelin basic protein induces anterior uveitis in Lewis ratsJ Neuroimmunol199453165717519633
   PubMed Web of Science ®Google Scholar
• ShaoHInduction of autoimmune encephalomyelitis and uveitis in B6 and (B6 × SJL) mice by peptides derived from myelin/oligodendrocyte glycoproteinJ Neuroimmunol20021321–211712212417441
   PubMed Web of Science ®Google Scholar
• ConstantinescuCSConstantinescuLEAnterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mousemodel ofmultiple sclerosis (MS)Curr Eye Res2000201717610611718
   PubMed Web of Science ®Google Scholar
• TeigeIIFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitisJ Immunol20031709477648412707359
   PubMed Web of Science ®Google Scholar
• GuoBThe type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in miceJ Clin Invest200811851680169018382764
   PubMed Web of Science ®Google Scholar
• OkadaAAEffect of type I interferon on experimental autoimmune uveoretinitis in ratsOcul Immunol Inflamm1998642152269924918
   PubMed Web of Science ®Google Scholar
• StubigerNInterferon alpha 2a in IRPB-derived peptide-induced EAU – part IAdv Exp Med Biol200352853754012918759
   PubMed Web of Science ®Google Scholar
• SuzukiJOral administration of interferon-beta suppresses experimental autoimmune uveoretinitisGraefes Arch Clin Exp Ophthalmol2002240431432111981647
   PubMed Web of Science ®Google Scholar
• MizuguchiJType I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitisArch Immunol Ther Exp (Warsz)200250424325412371620
   PubMed Web of Science ®Google Scholar
• BrassardDLInterferon-alpha as an immunotherapeutic proteinJ Leukoc Biol200271456558111927642
   PubMed Web of Science ®Google Scholar
• PfefferLMBiological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferonsCancer Res19985812248924999635566
   PubMed Web of Science ®Google Scholar
• GogasHPrognostic significance of autoimmunity during treatment of melanoma with interferonN Engl J Med2006354770971816481638
   PubMed Web of Science ®Google Scholar
• TreuschMInfluence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet’s diseaseRheumatology (Oxford)200443101275128215252211
   PubMed Web of Science ®Google Scholar
• KotterICytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literatureClin Exp Rheumatol2005234 Suppl 38S20S2616273760
   PubMed Web of Science ®Google Scholar
• YangDSInterferon-alpha in the management of patients with Behcet’s diseaseBr J Hosp Med (Lond)2008691057557918949947
   PubMed Web of Science ®Google Scholar
• WangWEffects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17Clin Cancer Res200814248314832019088050
   PubMed Web of Science ®Google Scholar
• ZhangXIFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulationJ Immunol200918263928393619265172
   PubMed Web of Science ®Google Scholar
• IwakuraYIshigame H. The IL-23/IL-17 axis in inflammationJ Clin Invest200611651218122216670765
   PubMed Web of Science ®Google Scholar
• KertesPJIntravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot studyCan J Ophthalmol19973231851889131284
   PubMed Web of Science ®Google Scholar
• YaziciHA controlled trial of azathioprine in Behcet’s syndromeN Engl J Med19903222812852404204
   PubMed Web of Science ®Google Scholar
• NussenblattRBEffectiveness of cyclosporin therapy for Behcet’s diseaseArthritis Rheum19852866714004976
   PubMed Web of Science ®Google Scholar
• Tugal-TutkunIEfficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trialArthritis Rheum20055282478248416052571
   PubMed Web of Science ®Google Scholar
• TsambaosDBehcet’s syndrome: treatment with recombinant leukocyte alpha-interferonArch Dermatol Res198627843353363740944
   PubMed Web of Science ®Google Scholar
• FeronEJInterferon-à2b for refractory ocular Behcet’s diseaseLancet1994343891014287910903
   PubMed Web of Science ®Google Scholar
• KotterIDifferential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trialSemin Arthritis Rheum200433531131915079762
   PubMed Web of Science ®Google Scholar
• AlpsoyEInterferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind studyArch Dermatol2002138446747111939808
   PubMed Web of Science ®Google Scholar
• CalguneriMEffects of interferon alpha treatment on the clinical course of refractory Behcet’s disease: an open studyAnn Rheum Dis200362549249312695172
   PubMed Web of Science ®Google Scholar
• WechslerBEfficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet’s diseaseOcul Immunol Inflamm20008429330111262659
   PubMed Web of Science ®Google Scholar
• KrauseLInterferon alfa-2a in the treatment of ocular Adamantiades-Behcet’s diseaseAdv Exp Med Biol200352851151912918754
   PubMed Web of Science ®Google Scholar
• Tugal-TutkunIResults of interferon-alfa therapy in patients with Behcet uveitisGraefes Arch Clin Exp Ophthalmol2006244121692169516673135
   PubMed Web of Science ®Google Scholar
• KrauseLLong term visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2aJ Rheumatol200835589690318412306
   PubMed Web of Science ®Google Scholar
• KotterIThe use of interferon alpha in Behcet disease: review of the literatureSemin Arthritis Rheum200433532033515079763
   PubMed Web of Science ®Google Scholar
• ZouboulisCCOrfanosCETreatment of Adamantiades-Behcet disease with systemic interferon alfaArch Dermatol19981348101010169722733
   PubMed Web of Science ®Google Scholar
• BodaghiBEfficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsBr J Ophthalmol200791333533917050581
   PubMed Web of Science ®Google Scholar
• GueudryJLong-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet diseaseAm J Ophthalmol2008146683784419027420
   PubMed Web of Science ®Google Scholar
• Guillaume-CzitromSEfficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s diseaseRheumatology (Oxford)200746101570157317702770
   PubMed Web of Science ®Google Scholar
• SfikakisPPAnti-TNF therapy in the management of Behcet’s disease – review and basis for recommendationsRheumatology (Oxford)200746573674117403712
   PubMed Web of Science ®Google Scholar
• HatemiGEULAR recommendations for the management of Behcet diseaseAnn Rheum Dis200867121656166218245110
   PubMed Web of Science ®Google Scholar
• LimJIAnterior granulomatous uveitis in patients with multiple sclerosisOphthalmology1991981421452008270
   PubMed Web of Science ®Google Scholar
• MeislerDMAnterior uveitis and multiple sclerosisCleve Clin J Med1989565355382766545
   PubMed Web of Science ®Google Scholar
• BregerBCLeopoldIHThe incidence of uveitis in multiple sclerosisAm J Ophthalmol1966625405455920437
   PubMed Web of Science ®Google Scholar
• BiousseVMultiple sclerosis associated with uveitis in two large clinic-based seriesNeurology19995211791819921871
   PubMed Web of Science ®Google Scholar
• ValentincicNVitreous hemorrhage in multiple sclerosis-associated uveitisOcul Immunol Inflamm2007151192517365802
   PubMed Web of Science ®Google Scholar
• BeckerMDInterferon as a treatment for uveitis associated with multiple sclerosisBr J Ophthalmol200589101254125716170111
   PubMed Web of Science ®Google Scholar
• DeuterCMInterferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot studyRetina200626778679116963852
   PubMed Web of Science ®Google Scholar
• BeckerMFirst results of a randomized controlled clinical trial comparing interferon beta with methotrexate for the treatment of intermediate uveitis with macular edemaInvest Ophthalmol Vis Sci200849E-Abstract 1118.
   Google Scholar
• RothovaACauses and frequency of blindness in patients with intraocular inflammatory diseaseBr J Ophthalmol1996803323368703885
   PubMed Web of Science ®Google Scholar
• MackensenFIntravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyRetina2008281414518185136
   PubMed Web of Science ®Google Scholar
• RothovaAMedical treatment of cystoid macular edemaOcul Immunol Inflamm200210423924612854032
   PubMed Web of Science ®Google Scholar
• MissottenTOctreotide long-acting repeatable for the treatment of chronic macular edema in uveitisAm J Ophthalmol2007144683884317916316
   PubMed Web of Science ®Google Scholar
• SchillingHLong-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammationRetina200525218218815689809
   PubMed Web of Science ®Google Scholar
• DeuterCMEfficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitisBr J Ophthalmol200993790691319321469
   PubMed Web of Science ®Google Scholar
• PlskovaJInterferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitisAm J Ophthalmol20071441556117601428
   PubMed Web of Science ®Google Scholar
• MackensenFInterferon therapy for ocular diseaseCurr Opin Ophthalmol200617656757317065927
   PubMed Web of Science ®Google Scholar
• KotterIHuman recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitisBr J Ophthalmol200387442343112642304
   PubMed Web of Science ®Google Scholar
• DeuterCMBehcet’s disease: ocular effects and treatmentProg Retin Eye Res200827111113618035584
   PubMed Web of Science ®Google Scholar
• PfefferLMRole of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expressionJ Biol Chem200427930313043131115131130
   PubMed Web of Science ®Google Scholar
• YangCHIFNalpha/beta promotes cell survival by activating NF-kappa BProc Natl Acad Sci U S A20009725136311363611095741
   PubMed Web of Science ®Google Scholar
• HamuryudanVInterferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open studyIsr Med Assoc J2002411 Suppl92893012455182
   PubMed Web of Science ®Google Scholar
• PozzilliCMonthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosisJ Neurol20022491505611954868
   PubMed Web of Science ®Google Scholar
• VermerschPCombination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosisEur J Neurol2007141858917222119
   PubMed Web of Science ®Google Scholar
• RavnborgMTreatment with azathioprine and cyclic methyl-prednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosisMult Scler200915332332819028832
   PubMed Web of Science ®Google Scholar
• PanitchHBenefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialJ Neurol Sci20052391677416169561
   PubMed Web of Science ®Google Scholar
• PanettaJDGilaniNInterferon induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infectionAliment Pharmacol Ther2009622 [Epub ahead of print].
   Web of Science ®Google Scholar
• WillsonRAVisual side effects of pegylated interferon during therapy for chronic hepatitis C infectionJ Clin Gastroenterol200438871772215319658
   PubMed Web of Science ®Google Scholar
• CuthbertsonFMIs screening for interferon retinopathy in hepatitis C justified?Br J Ophthalmol200488121518152015548803
   PubMed Web of Science ®Google Scholar
• d’AlterocheLOphthalmologic side effects during alpha-interferon therapy for viral hepatitisJ Hepatol2006441566116223542
   PubMed Web of Science ®Google Scholar
• OhiraMRetinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosisKeio J Med2009581545619398885
   PubMedGoogle Scholar
• SaitoHRetinopathy in a multiple sclerosis patient undergoing interferon-therapyMult Scler200713793994017468441
   PubMed Web of Science ®Google Scholar
• FoldenDVInterferon beta-associated retinopathy in patients treated for multiple sclerosisNeurology200870(13 Pt 2):1153115518362275
   PubMed Web of Science ®Google Scholar